Treatment Outcome and Chemoresistance-Related Factors of Low-Risk Gestational Trophoblastic Neoplasia: Results From a Tertiary Care Center in Saudi Arabia
- 1 December 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500172
Abstract
PURPOSE: Gestational trophoblastic neoplasia (GTN) is a highly curable malignancy classified using the International Federation of Gynecology and Obstetrics (FIGO)/WHO scoring system into low-risk (score 0-6) and high-risk (score ≥ 7) categories. Although single-agent chemotherapy is standard for low-risk GTN, patients with FIGO scores of 5-6 exhibit disproportionately high rates of chemoresistance, raising concerns about current classification and treatment strategies. METHODS: This retrospective analytic study included 162 patients with low-risk GTN treated at a tertiary referral center in Saudi Arabia from 1980 to 2021. Patients were stratified into FIGO score subgroups (0-4 v 5-6), and data on demographics, treatment regimens, outcomes, and chemoresistance were collected. The primary outcome was resistance to first-line chemotherapy. Multivariable logistic regression identified independent predictors of chemoresistance. RESULTS: The median patient age was 35 years, with 64.8% age 40 years and younger. Hydatidiform mole was the most common antecedent pregnancy (88.9%), and 30.9% had FIGO scores of 5-6. First-line treatment included single-agent chemotherapy (74.7%) and multiagent regimens (25.3%). Although all patients achieved complete remission, 26.5% exhibited chemoresistance to first-line treatment, significantly associated with treatment before the year 2000, higher FIGO scores, and single-agent chemotherapy. On multivariable analysis, FIGO scores of 5-6 (odds ratio [OR], 2.6; P = .02) and single-agent chemotherapy (OR, 0.11; P = .007) were independent predictors of resistance. β-human chorionic gonadotropin (hCG) level was the only FIGO component independently linked to chemoresistance. Relapse occurred in 5.4% of cases. CONCLUSION: Patients with FIGO scores of 5-6 and high β-hCG levels had increased resistance to first-line therapy. β-hCG was the strongest independent predictor. These findings highlight the need to reassess treatment strategies for this subgroup.Keywords
This publication has 25 references indexed in Scilit:
- Diagnosis and management of gestational trophoblastic disease: 2021 updateInternational Journal of Gynecology & Obstetrics, 2021
- Treatment of low-risk gestational trophoblastic neoplasiaBest Practice & Research Clinical Obstetrics & Gynaecology, 2021
- Classification systems in Gestational trophoblastic neoplasia - Sentiment or evidenced based?Cancer Treatment Reviews, 2017
- Gestational trophoblastic neoplasia: treatment outcomes from a single institutional experienceClinical and Translational Oncology, 2014
- Gestational trophoblastic disease in the western region of Saudi Arabia (single-institute experience)European Journal of Obstetrics & Gynecology and Reproductive Biology, 2014
- The outcome of patients with low risk gestational trophoblastic neoplasia treated with single agent intramuscular methotrexate and oral folinic acidEuropean Journal of Cancer, 2013
- Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: Factors associated with resistance to single-agent methotrexate chemotherapyGynecologic Oncology, 2012
- Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform moleAmerican Journal of Obstetrics and Gynecology, 2010
- Current management of gestational trophoblastic diseasesGynecologic Oncology, 2009
- Risk and prognostic factors in trophoblastic neoplasiaCancer, 1976